BIOCRYST PHARMACEUTICA

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

27 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2022 Financial Results on May 5

21 Apr 2022 07:00:52 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

11 Apr 2022 08:30:49 By Nasdaq GlobeNewswire

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

08 Apr 2022 09:15:13 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2022 07:15:42 By Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

24 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

23 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

09 Feb 2022 07:00:00 By Nasdaq GlobeNewswire